IMR Press / CEOG / Volume 44 / Issue 4 / DOI: 10.12891/ceog3940.2017

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 46 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Open Access Case Report
Marked improvement of severe gastroparesis following high dosage, but very well tolerated, dextroamphetamine sulfate
Show Less
1 Cooper Medical School of Rowan University, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology & Infertility, Camden, NJ, USA
2 Cooper Institute for Reproductive and Hormonal Disorders, P.C., Mt. Laurel, NJ, USA
Clin. Exp. Obstet. Gynecol. 2017, 44(4), 611–612;
Published: 10 August 2017
Purpose: To determine if treatment with dextroamphetamine sulfate could provide palliation for severe treatment refractory gastroparesis. Materials and Methods: Dextroamphetamine sulfate 15 immediate release tablets were initiated and the dose titrated upwards according to the degree of improvement vs. side effects. Results: The large majority of the symptoms of abdominal pain, very severe vomiting, and diarrhea was markedly improved but it took a very high dosage of amphetamine salts (150 mg). This dosage, however, did not cause any side effects. Conclusions: The gynecologist, who also is frequently asked to evaluate gastrointestinal (GI) symptomatology, is more cognizant of the increased cellular permeability syndrome, and thus may be called upon to treat certain GI conditions that should be more appropriate for the GI specialist to treat. The more articles that appear in the literature, the better the chance to promulgate the knowledge of these conditions, e.g., gastroparesis, to other specialties.
Increased cellular permeability syndrome
Dextroamphetamine sulfate
Sympathomimetic amines
Back to top